Rapid establishment and/or termination of substantial steady-state drug delivery
AssigneeIntarcia Therapeutics, Inc.
InventorsThomas R. Alessi, Kenneth L. Luskey
Life of this patent
Estimating the term…
Loading patent…
AssigneeIntarcia Therapeutics, Inc.
InventorsThomas R. Alessi, Kenneth L. Luskey
Estimating the term…
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.
A method of treating type 2 diabetes mellitus in a subject in need of treatment, comprising:
Dependencies are inferred from the claim text.